XML 19 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
 3 Months Ended
Dec. 31, 2016
Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,107,561) $ (2,012,326)
Adjustments to reconcile net loss to net cash (used in) operating activities    
Depreciation and amortization 22,327 53,722
Issuance of capital stock for services and expenses 206,831 104,476
Conversion of interest 56,454 0
Stock based compensation 10,887 11,837
Gain on sale of assets (1,034) 0
Loss on change - derivative liability 417,432 1,345,960
Amortization of debt discount 10,000 0
Provision for losses on accounts receivable 121,041 0
Impairment of goodwill 483,645 0
Changes in operating assets and liabilities:    
Accounts receivable 52,443 7,768
Prepaid expenses 3,250 (5,861)
Inventory 84,501 28,888
Accounts payable - trade and accrued expenses 66,556 (81,196)
Deferred revenue 0 (2,500)
NET CASH (USED IN) OPERATING ACTIVITIES (573,228) (548,928)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Investment in BioMedx, Inc., net 0 0
Proceeds from sale of equipment 1,034 0
NET CASH PROVIDED BY INVESTING ACTIVITIES: 1,034 0
CASH FLOWS FROM FINANCING ACTIVITIES:    
(Repayments) proceeds from line of credit (35,268) 221,457
Proeeds from warrant exercises 0 16,264
Proceeds from convertible notes payable 300,000 370,000
Proceeds from issuance of common/preferred stock, net of costs 300,000 0
NET CASH PROVIDED BY FINANCING ACTIVITIES 564,732 607,721
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (7,462) 58,793
CASH AND CASH EQUIVALENTS, beginning of period 188,309 82,266
CASH AND CASH EQUIVALENTS, end of period 180,847 141,059
Supplemental disclosures of cash flow information:    
Interest paid 14,245 15,190
Taxes paid $ 0 $ 0